135 related articles for article (PubMed ID: 31296449)
1. Hepatotoxicity of immune check point inhibitors: Approach and management.
Lleo A; Rimassa L; Colombo M
Dig Liver Dis; 2019 Aug; 51(8):1074-1078. PubMed ID: 31296449
[TBL] [Abstract][Full Text] [Related]
2. A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer.
Zou R; Hao Y; Wang Y; Yan F; Peng X; Huang Z; Chen G
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1918. PubMed ID: 38073600
[TBL] [Abstract][Full Text] [Related]
3. [Strategies for immunotherapy-related hepatotoxicity in liver cancer].
Zhi Y; Mao YM
Zhonghua Gan Zang Bing Za Zhi; 2023 Nov; 31(11):1125-1128. PubMed ID: 38238943
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
Cunningham M; Gupta R; Butler M
Hepatology; 2024 Jan; 79(1):198-212. PubMed ID: 36633259
[TBL] [Abstract][Full Text] [Related]
5. Immune-mediated hepatitis: Basic concepts and treatment.
Velarde-Ruiz Velasco JA; Tapia Calderón DK; Cerpa-Cruz S; Velarde-Chávez JA; Uribe Martínez JF; García Jiménez ES; Aldana Ledesma JM; Díaz-González Á; Crespo J
Rev Gastroenterol Mex (Engl Ed); 2024; 89(1):106-120. PubMed ID: 38485561
[TBL] [Abstract][Full Text] [Related]
6. Adverse Events of Oncologic Immunotherapy and Their Management.
Barber FD
Asia Pac J Oncol Nurs; 2019; 6(3):212-226. PubMed ID: 31259216
[TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibitor Rechallenge After Immune-Related Adverse Events in Patients With Cancer.
Dolladille C; Ederhy S; Sassier M; Cautela J; Thuny F; Cohen AA; Fedrizzi S; Chrétien B; Da-Silva A; Plane AF; Legallois D; Milliez PU; Lelong-Boulouard V; Alexandre J
JAMA Oncol; 2020 Jun; 6(6):865-871. PubMed ID: 32297899
[TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy.
Rajha E; Chaftari P; Kamal M; Maamari J; Chaftari C; Yeung SJ
Gastroenterol Rep (Oxf); 2020 Feb; 8(1):25-30. PubMed ID: 32104583
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
10. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
[TBL] [Abstract][Full Text] [Related]
11. Principles of prophylactic and therapeutic management of skin toxicity during treatment with checkpoint inhibitors.
Kamińska-Winciorek G; Cybulska-Stopa B; Lugowska I; Ziobro M; Rutkowski P
Postepy Dermatol Alergol; 2019 Aug; 36(4):382-391. PubMed ID: 31616210
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune complications of immunotherapy: pathophysiology and management.
Chan KK; Bass AR
BMJ; 2020 Apr; 369():m736. PubMed ID: 32253223
[TBL] [Abstract][Full Text] [Related]
13. HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis.
Correale P; Saladino RE; Giannarelli D; Sergi A; Mazzei MA; Bianco G; Giannicola R; Iuliano E; Forte IM; Calandruccio ND; Falzea AC; Strangio A; Nardone V; Pastina P; Tini P; Luce A; Caraglia M; Caracciolo D; Mutti L; Tassone P; Pirtoli L; Giordano A; Tagliaferri P
Cells; 2020 Aug; 9(9):. PubMed ID: 32854442
[TBL] [Abstract][Full Text] [Related]
14. Hypoproteinemia being a manifestation of immunotherapy-related liver dysfunction.
Deng J; Chen X; Sun H; Liu Y; Li W; Chen B; Zhao S; Jia K; Wang H; Guo H; Jiang M; Xu Y; He Y; Zhou C
Ann Transl Med; 2020 Jul; 8(14):889. PubMed ID: 32793733
[TBL] [Abstract][Full Text] [Related]
15. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
16. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy.
Haanen J; Ernstoff M; Wang Y; Menzies A; Puzanov I; Grivas P; Larkin J; Peters S; Thompson J; Obeid M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32532839
[TBL] [Abstract][Full Text] [Related]
17. Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer.
Khan Z; Di Nucci F; Kwan A; Hammer C; Mariathasan S; Rouilly V; Carroll J; Fontes M; Ley Acosta S; Guardino E; Chen-Harris H; Bhangale T; Mellman I; Rosenberg J; Powles T; Hunkapiller J; Chandler GS; Albert ML
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12288-12294. PubMed ID: 32430334
[TBL] [Abstract][Full Text] [Related]
18. Immune Checkpoint Inhibitor-Associated Primary Adrenal Insufficiency: WHO VigiBase Report Analysis.
Grouthier V; Lebrun-Vignes B; Moey M; Johnson DB; Moslehi JJ; Salem JE; Bachelot A
Oncologist; 2020 Aug; 25(8):696-701. PubMed ID: 32390168
[TBL] [Abstract][Full Text] [Related]
19. Immune-Related Oral, Otologic, and Ocular Adverse Events.
Srivastava A; Al-Zubidi N; Appelbaum E; Gombos DS; Nader ME; Gidley PW; Chambers MS
Adv Exp Med Biol; 2020; 1244():295-307. PubMed ID: 32301024
[TBL] [Abstract][Full Text] [Related]
20. Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors.
Choi J; Lee SY
Immune Netw; 2020 Feb; 20(1):e9. PubMed ID: 32158597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
